PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.

Daniels, Stephen

PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study. [electronic resource] - Journal of clinical lipidology - 322-330.e5 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

1933-2874

10.1016/j.jacl.2020.03.001 doi


Adolescent
Antibodies, Monoclonal, Humanized--therapeutic use
Anticholesteremic Agents--therapeutic use
Child
Double-Blind Method
Female
Heterozygote
Humans
Hyperlipoproteinemia Type II--drug therapy
Male
Middle Aged
PCSK9 Inhibitors
Treatment Outcome